Aziguli Maihemaiti

Ueruemqi, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle.

Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: December 15, 2025

Imeglimin Exerts Anti-Tumor Activity in Multiple Myeloma Through Affecting Energy Metabolism and Downregulating IL-16 Expression.

Imeglimin Exerts Anti-Tumor Activity in Multiple Myeloma Through Affecting Energy Metabolism and Downregulating IL-16 Expression.

Journal: Cancer medicine

Published: September 12, 2025

Research on the correlation and potential mechanism of PKCδ expression with efficacy and prognosis in diffuse large B-cell lymphoma.

Research on the correlation and potential mechanism of PKCδ expression with efficacy and prognosis in diffuse large B-cell lymphoma.

Journal: Frontiers in oncology

Published: August 21, 2025

EPAS1 increases SDHA to inhibit proliferation of multiple myeloma cells by restoring TCA Cycle.

EPAS1 increases SDHA to inhibit proliferation of multiple myeloma cells by restoring TCA Cycle.

Journal: NPJ precision oncology

Published: February 20, 2025

Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.

Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.

Journal: Hematology (Amsterdam, Netherlands)

Published: November 29, 2023

Update on the outcome of M-protein screening program of multiple myeloma in China: A 7-year cohort study.

Update on the outcome of M-protein screening program of multiple myeloma in China: A 7-year cohort study.

Journal: Cancer medicine

Published: June 06, 2023

The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.

The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.

Journal: Cancer medicine

Published: November 09, 2022

Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.

Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.

Journal: Annals of hematology

Published: September 17, 2022

The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.

The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.

Journal: Cancer

Published: July 20, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026